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This review illustrates notable recent progress in the field of medicinal bioinorganic
chemistry with many new approaches to the design of innovative metal-based anticancer
drugs emerging. Current research addressing the problems associated with platinum drugs
has focused on other metal-based therapeutics that have different modes of action, and on
prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin
chemotherapy.
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21. Introduction
Metals, and in particular transition metals, offer potential advantages over the more
common organic-based drugs, including; a wide range of coordination numbers and
geometries, accessible redox states, ‘tune-ability’ of the thermodynamics and kinetics of
ligand substitution, as well as a wide structural diversity. Medicinal inorganic chemistry is a
thriving area of research [1-4], initially fueled by the discovery of the
metallopharmaceutical, cisplatin about 40 years ago. Today, over 30 years after its approval
as a chemotherapeutic agent, cisplatin is still one of the world’s best selling anticancer
drugs. It is mainly used in the treatment of ovarian, head and neck, bladder, cervical and
lymphomas cancers. Over the past decades, a large number of cisplatin analogs have been
screened as potential antitumor agents, but of these only two, carboplatin and oxaliplatin,
have entered world-wide clinical use [5].
Regardless of the achievements of current platinum drugs, there are some major
drawbacks: they are efficient only for a limited range of cancers, some tumors can have
acquired or intrinsic resistance, and they often cause severe side-effects like nausea, bone
marrow suppression and kidney toxicity. Although currently about ten other platinum
compounds are in clinical trials, the cisplatin derivatives have not been able to address
sufficiently many of the disadvantages associated with cisplatin. There is, therefore, a need
for new approaches that are purposefully designed to circumvent these drawbacks. The
field of metal-based anticancer drug design can be divided into two different approaches;
classical and non-classical chemotherapeutics [6,7].
Cisplatin’s mode of action involves distortion to DNA. Here we use the term classical
chemotherapeutics to refer to drugs that target DNA. Classical drugs based on other metals
can address the problems associated with platinum drugs and are attracting increasing
interest. At present, a number of metal-based compounds are known to have promising
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antiproliferative effects in a wide range of tumors with novel modes of DNA binding; this
will be discussed in the section “Classical non-platinum metal compounds”.
Recent progress in the field of cell biology has resulted in the discovery of receptors
and growth factors that are up-regulated in cancer cells. These provide new targets for
anticancer drug design. Examples of non-classical chemotherapeutics with proteins and
enzymes as targets are emerging; this will be discussed in the section “Non-classical metal
compounds”.
In addition, there is continuing interest in designing drugs that can be activated
selectively in the tumor by cellular processes or controlled external activation. Extensive
studies on the behavior of metal complexes under biologically-relevant conditions have
revealed some promising approaches for targeted anticancer drug design with classical and
non-classical targets (section 4).
The metals discussed in this review are highlighted in Figure 1.
FIGURE 1. Periodic table with color coding for the metals discussed in this review
4Classical non-platinum metal compounds
Nuclear DNA is considered to be the ultimate target of cisplatin and related platinum
therapeutics. Prior to DNA attack, cisplatin undergoes aquation. Although the activated
(aquated) cisplatin can interact with other biomolecules, its antitumor activity derives from
its capability to form bifunctional DNA cross-links, which causes the DNA to distort (kink,
Figure 2a [8]). The platinum-induced kink in the DNA is considered to be the critical lesion
leading to a chain of events which includes protein recognition (e.g. by HMG) and eventual
apoptosis [9].
In this section some examples of other metal-based therapeutics that target DNA are
given. Their exploration may result in drugs that produce distinctly different lesions on
DNA and overcome acquired or inherent cisplatin resistance, or may prove to be more
active towards tumors which are non-responsive to current chemotherapy.
Ruthenium
Ruthenium compounds containing RuII or RuIII are considered to be suitable
candidates for anticancer drug design, since they exhibit a similar spectrum of kinetics for
their ligand substitution reactions as platinum(II). A number of ruthenium compounds have
been shown to display promising anticancer activity and two ruthenium(III) complexes
have entered clinical trials, trans-[RuCl4(DMSO)(Im)]ImH (NAMI-A, where Im =
imidazole, Figure 2b), and trans-[RuCl4(Ind)2]IndH (KP1019, where Ind = indazole,
Figure 2c). NAMI-A is more active against metastases than against primary tumors [10]. In
contrast, the structurally-similar KP1019 is active against primary tumors [11]. It is
believed that the activity of the ruthenium(III) compounds is dependent on the in vivo
reduction to the more reactive ruthenium(II) species [12]. This has led to increased interest
5in the anticancer potential of ruthenium(II) compounds. Much work has focused on the
anticancer potential of half-sandwich Ru(II) arene complexes of the type, [(η6-
arene)Ru(YZ)(X)], where YZ is a bidentate chelating ligand and X is a good leaving group
e.g. Cl, Figure 2d). These half-sandwich “piano-stool” complexes offer great scope for
design, with the potential to vary each of the building blocks (arene, chelated ligand YZ,
and monodentate ligand X) to allow modifications of thermodynamic and kinetic
parameters.
Some of the half-sandwhich Ru(II) arene complexes display promising in vitro and in
vivo anticancer activity [13] (Figure 2e and f). These monofunctional compounds bind
coordinatively to N7 of guanine in DNA which can be complemented by intercalative
binding of an extended arene as well as specific hydrogen-bonding interactions between the
chelating ligand and C6O of guanine [14]. These additional interactions result in unique
modes of binding to duplex DNA and structural distrortions that differ significantly from
those caused by cisplatin [15] (Figure 2g). This may explain why these compounds are not
cross-resistant with cisplatin. Indeed, it has been found that increasing the size of the
coordinated arene increases their activity in the human ovarian cancer cell line [13].
Changing the chelating ligand in these ruthenium arene complexes also appears to have an
enormous effect on their kinetics and even changes their nucleobase selectivity [16]. It is
believed that in vivo the aquation of the chloro complex is largely suppressed in
intracellular fluids where high chloride concentrations are found (100 mM), whereas in the
cell nucleus, where the chloride concentration is lower (4 mM), the complex forms
predominately the active aqua species [17].
Another interesting class of ruthenium compounds containing arylazopyridine (azpy)
ligands shows promising cytotoxic activity that is structurally-dependent. Three of the five
possible isomers of [Ru(azpy)2Cl2] (α, β, λ, Figure 2h) have been reported, where the α 
6isomer represents the cis,trans,cis, β the cis,cis,cis and γ the trans,cis,cis orientation of the
chlorides, the pyridine and the azo nitrogens, respectively. The α and λ isomers show 
higher toxicities compared to the β isomer [18]. Indeed, DFT calculations suggest that the 
ability of the isomers to intercalate into DNA decreases from λ >α > β isoforms [19]. 
Recently several isomeric forms of multinuclear ruthenium complexes with bridging azpy
ligands have been reported [20]; t he γ/γ isomeric form exhibits the highest cytotoxicity, 
over 30-fold higher than cisplatin in breast cancer cells.
Osmium
The anticancer potential of osmium, the heavier congener of ruthenium has recently
been explored. Osmium complexes have a reputation for being either toxic (OsO4) or
substitution-inert (OsII and OsIII complexes), and as a consequence their therapeutic
potential has been little explored. However, Sadler and coworkers have synthesized some
osmium(II) arene complexes with cancer cell cytotoxicity that is comparable to the clinical
drugs carboplatin and cisplatin (Figure 2i and j) [21,22]. This was achieved by
systematically varying the nature of the chelating ligand to fine-tune both the kinetics and
thermodynamics of reactions of the osmium compounds in aqueous solution [23,24]. The
OsII arenes are believed to interact with DNA in a similar fashion as their ruthenium
analogs, i.e. binding to N7 of guanine in combination with H-bonding and non-covalent
arene DNA interaction. Interestingly, binding of OsII arenes to calf thymus DNA gives rise
to a large unwinding of double-helical DNA, unlike cisplatin which causes DNA bending
[25]. These osmium complexes do not display cross-resistance with cisplatin towards
cancer cells, suggesting promise for addressing the problem of intrinsic or acquired
resistance in chemotherapy.
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FIGURE 2. Examples of metal-based compounds that target DNA. (a) X-ray structure showing the
kinking of DNA by cisplatin (pdb1aio) (b) NAMI-A. (c) KP1019. (d) General structure of
organometallic ruthenium(II) and osmium(II) arene complexes. (e, f) Examples of cytotoxic RuII
arene complexes. (g) model showing intercalation of a RuII arene complex into DNA. (h) [γ-
Ru(azpy)2Cl2]. (i, j) Examples of cytotoxic OsII arene complexes.
Non-classical metal compounds
The traditional platinum-based therapeutics and the organometallic complexes discussed in
the previous section owe their anticancer activity to their non-repairable interaction with
DNA and make use of the fast replication and mitotic processes of malignant cells. Drugs
that are able to target cellular signaling pathways over-expressed in cancer cells provide
8attractive approaches for anticancer drug design. Although less studied than the
metallodrug-DNA interactions, some examples of metallodrugs that interact with specific
proteins and enzymes are given below.
Gold
Gold complexes are well known pharmaceuticals, mainly for their application as
drugs to treat rheumatoid arthritis. Some tetrahedral Au(I) phosphine complexes display a
wide spectrum of anticancer activity in vivo, especially in towards cisplatin-resistant cell
lines [26]. Their cytotoxicity is mediated by their ability to inhibit mitochondrial human
glutathione reductase (hGR) and thioredoxin reductase (hTrxR) irreversibly [27]. In
particular, phosphol-containing gold(I) complexes (Figure 3a) are highly potent, nanomolar
inhibitors of both hGR and hTrxR [28]. hTrxR is associated with many cellular processes
such as antioxidant defence and redox homeostasis, and is found at elevated levels in
human tumor cell lines.
Gold(III) is isoelectronic and isostructural with Pt(II), therefore gold(III) analogues of
Pt(II) drugs were investigated for their biological potential soon after the appearance of
cisplatin in the clinic. Unfortunately they were found to be relatively unstable as well as
easily reduced to metallic gold under physiological conditions [29]. In recent years,
however, several gold(III) compounds that incorporate ligands to increase the stability to
the gold(III) centre have been reported. For example, gold(III) porphyrins(Figure 3b)
exhibit in vitro and in vivo activity in hepatocellular and nasopharyngeal carcinoma [30].
Other Gold(III) compounds with promising biological activity include gold(III) bipyridyl
compounds [31], dinuclear gold(III) oxo complexes [32] and gold(III) dithiocarbamates
[33]. For these compounds the mitochondria and the proteasome are thought to be targets
[34].
9Gallium
The chemical behavior of gallium(III) is similar to that of ferric iron (FeIII), but differs
in that GaIII is non-reducible under physiological conditions whereas FeIII is readily reduced
to FeII. This difference provides therapeutic potential for gallium(III). Currently, two
compounds, gallium tris-8-quinolinolate (KP46) and gallium tris-maltolate (Figure 3c and
d) are being investigated in clinical trials [35]. Their mechanism of action is associated with
the inhibition of ribonucleotide reductase (RR). The enzyme RR catalyses the conversion of
ribonucleotides to deoxyribonucleotides and is produced during the transition from the G1
to the S phase of the cell cycle as a prerequisite for DNA replication, and is highly
expressed in tumor cells.
Ruthenium
Interestingly, Meggers et al. have developed kinetically-inert organometallic
complexes that act as scaffolds to mimic the organic enzyme inhibitor staurosporine, a
potent inhibitor of various kinases. In these metal-based inhibitors the carbohydrate unit of
staurosporine is replaced with ruthenium fragments (Figure 3e) [36]. Structural variation by
substitution of the ligands on the metal results in picomolar protein kinase inhibitors. They
are highly toxic towards human melanoma cells. The ruthenium staurosporine bioconjugate
was recently investigated as an inhibitor for glycogen synthase kinase (GSK-3β), a major 
regulator of p53 localization and expression. The ruthenium staurosporine complex acts as
a potent p53 activator and induces apoptosis in otherwise chemoresistant melanoma cells
[37].
A family of organometallic RuII compounds containing monodentate
phosphaadamantane (pta) ligands, exhibits moderate in vitro activity and some compounds
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show no activity in healthy cells up to millimolar concentrations. The pta compounds show
little activity against primary tumors in vivo, although they exhibit some capacity to reduce
lung metastases derived from a mammary carcinoma xenograft grown in mice [38]. The
cytotoxicity of the RuII pta compound, [Ru(η6-p-cymene)Cl2(pta)] (Figure 3f), in EAC cells
is thought to be mediated by mitochondrial and JNK-p53 pathways [39].
Cobalt
Some hexacarbonyl dicobalt complexes exhibit promising activity against several
human cancer cell lines [40]. In particular, a cobalt-alkyne analogue of the anti-
inflammatory drug, aspirin, is potently active in breast cancer cell lines (Figure 3g). Its
toxicity has been attributed to its ability to inhibit cyclooxygenase (COX-1 and 2) [41].
This appears to be a promising approach, since inhibition of cyclooxygenase delays tumor
growth as well as improves response to conventional cancer therapies.
Another hexacarbonyl dicobalt series of compounds containing nucleoside ligands
(Figure 3h) displays antiproliferative activities with IC50 values in the range of 5–50 µM in
human breast cancer cell lines [42].
The family of cysteine cathepsin proteases has recently been validated as an important
enzymatic class to target in cancer. More specifically, cathepsin B and L have been shown
to be involved in multiple stages of tumor development. Metal-based compounds reported
to show promising inhibition of cathepsin B include linear gold(I) complexes containing
thiolate and phosphine ligands [43], dinuclear palladium complexes (biphosphinic
palladacycle complexes) [44], and several oxorhenium(V) complexes [45].
11
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Y = H, Me,
OMe, Br, Cl
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Other metal-based drugs in preclinical or early phase of clinical development not
mentioned in the previous two sections contain vanadium, rhodium, copper, bismuth and
lanthanide metals [46-48].
FIGURE 3. Examples of metal-based anticancer drugs that target proteins and enzymes. (a) Gold(I)
phosphole complex. (b) Gold(III) meso-tetraarylporphyrins complexes. (c) KP46. (d) Gallium tris-
maltolate. (e) DW1. (f) RuII arene complex containing a monodentate phosphaadamantane (pta)
ligand. (g) Cobalt-alkyne analogue of the anti-inflammatory drug aspirin. (h) Hexacarbonyl dicobalt
complex containing a nucleoside ligand.
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Prodrug stategies
Delivery of metal-based drugs to their targets poses one of the biggest challenges in cancer
chemotherapy. A drug needs to be sufficiently reactive to bind to the biological target, but
not so reactive that it will be deactivated by the many biomolecules encountered on the
way. One strategy involves the design of prodrugs. Prodrugs are drug derivatives that can
undergo a transformation in vivo to release the active species, with improved
physiochemical, biopharmaceutical and pharmacokinetic properties. For metal-based
therapeutics, this prodrug activation may be realized by a photochemical process [49],
oxidation or reduction of the metal, or ligand substitution. This requires extensive
knowledge of ligand substitution rates, redox potentials, photochemistry and choice of
metal but also the effect of the other coordinated ligands in the complex.
In recent years, the focus has been on making prodrugs selective. In order to achieve
this, the prodrug has to be activated by specific physiological characteristics of tumors, like
the reducing environment of the cell, pH, or cancer cell permeability. Some examples of
different prodrug strategies including tumor-selectivity and drug delivery strategies will be
discussed in the following paragraphs.
Photoactivation as a prodrug strategy
The activation of a metal-based prodrug can be realised by photochemical means. The
advantages of using light as an external stimulus is that it allows local treatment of the
tumor, so minimizing side-effects. The poor penetration of tissue by short-wavelength light
is, however, a serious limitation: longer wavelength light (red) penetrates more deeply than
UVA light. For a photochemical treatment to be effective in the clinic, the wavelength of
activation should be within the range 350-900 nm; shorter wavelengths cause damage to
tissue and higher wavelengths usually carry insufficient energy to activate the prodrug.
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Currently used in the clinic, Photodynamic therapy (PDT) treats readily accessible tumors
(i.e. skin, neck, bladder) by the administration of a non-toxic photosensitizer and
subsequent irradiation of the tumor site [50]. Upon irradiation, the photosensitizer, typically
a porphyrin, becomes excited and this energy is transferred to ground-state triplet oxygen
(3O2) to form highly reactive singlet oxygen (1O2), leading to cell death. Metal-bound
porphyrins can have marked effects on the tumor-localizing properties of the
photosensitizer. Indeed, metal-containing photosensitizers for cancer treatment are currently
well represented in clinical trials: including a lutetium porphyrin derivative (Lutetium
texaphyrin) [51,52], CGP55847 (Zn), Photosense (Al), and Purlytin (Sn) [53]. All these
photo-sensitizers need oxygen to generate their cytotoxic effects; however cancer cells are
often deficient in oxygen.
Rhodium
Recently, several Rh and Ru complexes have been shown to exhibit oxygen-
independent light-induced anticancer activity. For example, Barton et al. have shown that
several octahedral RhIII complexes with extended diimine ligands (Figure 4a), bind only
weakly to DNA in the absence of light but on photoactivation bind to DNA and cleave the
DNA backbone with high specificity for mismatched DNA [54,55]. Recently the effects of
variation of the ancillary ligand on the ability of these compounds to target DNA
mismatches in vitro and in vivo have been explored [56].
Platinum
The general kinetic inertness of PtIV complexes compared to PtII complexes has been
widely exploited in the design of potential prodrugs. The PtIV compound satraplatin,
[Pt(cha)Cl2(OAc)2(NH3)] (where cha is cyclohexylamine, Figure 4b), has recently been
14
abandoned in phase III clinical trials for the treatment of hormone-refractory prostate
cancer [57]. Substitution reactions of PtIV complexes under physiological conditions are
very slow or do not take place at all. Therefore, intracellular reduction to PtII is thought to
be essential for cytotoxic activity. This reduction may be achieved by cellular reducing
agents (discussed in the next section) or by irradiation with light, allowing site-specific
activation of the drugs [58].
Trans-dihydroxido platinum(IV) prodrugs containing two azido ligands in trans or cis
positions relative to each other are non-toxic in the dark but show cytotoxicity towards
various human cancer cell lines upon irradiation [59,60]. In particular, a PtIV diazido
complex containing pyridine trans to ammonia, trans,trans,trans-[Pt(N3)2(OH)2(py)(NH3)]
(Figure 4c), is up to 80 times more cytotoxic than cisplatin in ovarian cancer cells upon
irradiation, whilst inactive and stable towards biological reductants in the dark. One
photoactivation pathway for these complexes (amongst several possibilities) involves
ligand-to-metal charge transfer (LMCT) from the azido ligands to PtIV, resulting in
reduction to the reactive PtII species. The produces azidyl (N3·) radicals which rapidly
combine and decompose to produce nitrogen gas. Aquation of the PtII compound and
subsequent binding to DNA (and possibly proteins) leads to its cytotoxic effect. Notably,
the mechanism of DNA platination by the trans-azide complex is different from cisplatin
and cell death is not solely dependent on activation of the caspase 3 pathway [61]. It is
apparent that photoactivation can produce excited states with unusual reactivity and provide
routes to intervening in biological pathways not available to ground-state drugs.
Redox activation as a prodrug strategy
The redox behavior of metal complexes offers chemical reactivity that is not accessible to
purely organic molecules and therefore can yield novel metallodrugs with new mechanisms
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of drug action. For the prodrug to be successful, the metal complex should possess
biologically-accessible redox potentials. Tuning their properties to the reducing
environments of tumor cells may lead to novel targeted strategies.
Iron
Well established examples are ferrocene derivatives of the breast cancer drug tamoxifen
(Figure 4d) [62,63]. They display potent activity against both estrogen-dependent and
estrogen-independent breast cancer cells, whereas tamoxifen alone is active only against
estrogen-dependent cells. The activity of the ferrocene tamoxifen derivatives (ferrocifens)
in estrogen-independent cells is attributed to the redox properties of the FeII complex,
leading to oxidative damage to DNA. The mechanism of action of ferrocifens in estrogen-
dependent cells is likely to be similar to that of tamoxifen itself. It is noteworthy that one of
the most active ferrocene derivatives exhibits less toxicity than tamoxifen itself. A recent
study on ferrocene tamoxifen derivatives with modified side chains has established the
minimal structural requirements to obtain cytotoxicity [64].
Cobalt
A prodrug approach for the inhibition of enzymes by cobalt complexes has been
explored by Hambley et al. [65] Their strategy involves the complexation of the matrix
metalloproteinase (MMP) inhibitor marimastat to a CoIII complex to achieve selective
delivery of MMP to the tumor (Figure 4e). The resulting CoIII complex provides an inert
carrier system for the transportation of the inhibitor. The prodrug is activated by a
bioreduction pathway producing a labile CoII complex, which results in the release of the
MMP inhibitor. The hypoxic nature of the tumor should prevent oxidation back to the
cobalt(III) complex thus achieving selective release in tumor cells. Indeed, increased
16
cytotoxicity was observed for the cobalt prodrug in in vivo tumors in mice compared to the
MMP inhibitor alone. Unfortunately, both the inhibitor and the prodrug promote metastasis.
Ruthenium
Half-sandwich ruthenium arene complexes containing iodo and phenylazopyridine
ligands (Figure 4f) exhibit remarkable inertness towards ligand substitution in aqueous
solution, but are highly toxic in human ovarian and lung cancer cells. Whereas azopyridine
ligands alone are difficult to reduce, these azopyridine RuII complexes have reduction
potentials that are biologically accessible. The toxicity of these complexes can be attributed
to their ability to induce redox reactions inside the cell leading to reactive oxygen species
(ROS). Interestingly, the redox cycle involves the oxidation of the strong reducing agent
glutathione present in millimolar concentrations, in the presence of micromolar
concentrations of the ruthenium complex [66].
Organometallic ruthenium arene complexes containing thiolato ligands (e.g. Figure 4g)
can be activativated by oxidation [67]. Under physiologically-relevant conditions, the
monodentate thiolato ruthenium complex is capable of efficient acceptance of an oxygen
atom e.g. from an intermediate in glutathione (GSH) oxidation. This shows that GSH can
act as a source of reactive oxygen species, able to induce oxidation of organometallic
complexes which are themselves stable in air [68]. Ruthenium sulfenate adducts appear to
be more labile than the parent thiolato complexes (e.g. towards DNA binding) perhaps
through protonation of the sulfenato oxygen atom.
Platinum
The relative kinetic inertness of six-coordinate octahedral PtIV complexes can be used as
a prodrug approach in order to overcome some of the problems associated with (four-
17
coordinate. square-planar) cisplatin. For this, intracellular reduction to PtII is essential for
activation and cytotoxic activity. The two extra ligands in the axial positions allow the
inclusion of different kinds of bioactive ligands which may lead to platinum anticancer
complexes with improved efficacy.
In one such approach, an attempt to target specifically estrogen-positive, ER(+),
malignancies, such as breast and ovarian cancers, led to the design of several estrogen-
tethered platinum(IV) complexes (Figure 4h) [69]. This is a cancer drug target because
estrogen-receptor-positive breast cancer cells treated with estrogen are more sensitive to
cisplatin. Upon intracellular reduction, the complex releases cisplatin and two molecules of
estrogen derivative. The latter induces upregulation of the high-mobility group domain
protein HMGB1 in a human breast cancer cell line. The HMGB1 protein shields platinated
DNA from nucleotide-excision repair.
In an attempt to overcome cisplatin resistance, a similar approach has been used to
inhibit glutathione-S-transferase (GST), the main cellular defence against xenobiotics. For
this, Dyson et al. attached the GST inhibitor ethacrynic acid to a PtIV complex
(ethacraplatin, Figure 4i) [70].
Effort in recent years has also been given to the design of novel drug delivery systems
that are capable of increasing the cellular uptake as well as directed delivery of
metallodrugs to tumor cells only. Interesting approaches include attachment of a platinum
drug to a pH-sensitive polymer [71], attachment of a PtIV prodrug non-covalently to single-
walled carbon nanotubes [72], encapsulation of platinum drugs in lipid-based nanocapsules
[73] and attachment of the SV4-40T antigen nuclear localization signal to metallocenes
[74].
18
Ru
I
N
N
N
R2
R1
R1 = p-cymene, biphenyl
R2 = NMe2, OH, H
Pt
O
ClH3N
H3N Cl
O
H
N
O
O
O
O
O
O
O
N
H
O
O
O
O
O
n
n
(a) (b) (c) (d)
(e) (f) (g)
(h) (i)
Pt
O
O
NH3
N
H2
Cl
Cl
O
O
FIGURE 4. Prodrug strategies. (a) Example of a photoactivatable octahedral RhIII complex with an
extended diimine ligand. (b) Satraplatin. (c) Example of a photoactivatable trans-azido platinum(IV)
prodrug. (d) Ferrocifen. (e) Cobalt-marimastat bioconjugate. (f) RuII arene complexes containing
iodo and phenylplazopyridine ligand. (g) RuII arene complexes containing a thiolate ligand. (h)
Pt(IV)-estradiol bioconjugate. (i) Ethacraplatin.
Conclusions
Metal coordination complexes offer a very versatile platform for the design of novel
anticancer agents. Their properties can be quite distinct from those of purely organic
compounds. Particularly attractive for study are the first, second and third row transition
metals, with their variable oxidation states, coordination numbers and ability to bind to a
wide variety of types of ligands (e.g. halides, O, S, N, P, C). In particular metals in the
second and third rows often exchange their ligands relatively slowly, on minutes-to-hours
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timescales which allow at least some of the original ligands to remain bound to the metal en
route to the target site. In general (with some exceptions) because they can undergo ligand
exchanges, metal complexes are prodrugs, ligand substitution can activate the metal
complex towards binding to target molecules. A key element in the design process is the
control of both the thermodynamics (state of equilibrium) and kinetics of ligand
substitution events which can occur in vivo, for example the aquation of metal-chloride
bonds as the concentration diminishes from extracellular to intracellular (cytoplasmic and
nuclear) compartments.
Of interest too are both metal-centered and ligand-centered redox processes. The
former can trigger activation by ligand release (e.g. reduction of substitution inert CoIII to
labile CoII), and the latter the initiation of the production of reactive oxygen species (e.g.
azopyridine RuII arenes) as part of the cytotoxic mechanism. The possibility of using light
to activate metal complexes selectively in tumor cells is also an intriguing one. Reactions of
excited-state metal complexes can be distinctly different from those of ground-state
complexes, giving rise to the possibility of interfering in biochemical pathways with highly
reactive novel species.
Cisplatin and the successive generations of platinum-based anticancer drugs
(carboplatin and oxaliplatin) have demonstrated that metal coordination complexes can play
an important part in anticancer treatment regimes in the clinic. The exploration of other
transition metal complexes, as well as targeting and activation strategies, should lead to
future generations of drugs which can overcome some of the disadvantages associated with
cisplatin therapy, including the reduction of side-effects, widening the spectrum of activity,
and resistance.
Finally it is worth emphasizing the subtlety with which ligands control the reactivity
of transition metal ions, and also the reciprocal effects which metal ions can have on the
20
properties of ligands. Both the metal and the ligands can play important roles in the
recognition of target sites. The subtle effects exerted by ligands can be both steric and
electronic in nature. Modern theoretical methods (e.g. Amsterdam Density Functional
Theory) and techniques (e.g. high resolution electrospray mass spectrometry, multinuclear
polarization transfer NMR spectroscopy) are likely aid our understanding of the chemical
and biochemical reactivity of metal complexes and the construction of meaningful
structure-activity relationships. For this purpose, studies of the chemistry of metal
complexes under physiologically-relevant conditions (e.g. biological screening conditions)
become very important.
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